Predictors of Patient-Reported Incontinence at Adjuvant/Salvage Radiotherapy after Prostatectomy: Impact of Time between Surgery and Radiotherapy.
EPQ-R
ICIQ-SF
adjuvant radiotherapy
prostatectomy
salvage radiotherapy
urinary incontinence
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jun 2021
29 Jun 2021
Historique:
received:
07
05
2021
revised:
16
06
2021
accepted:
24
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
3
7
2021
Statut:
epublish
Résumé
Baseline urinary incontinence (UI) strongly modulates UI recovery after adjuvant/salvage radiotherapy (ART/SRT), inducing clinicians to postpone it "as much as possible", maximizing UI recovery but possibly reducing efficacy. This series aims to analyze the trend of UI recovery and its predictors at radiotherapy start. A population of 408 patients treated with ART/SRT enrolled in a cohort study (ClinicalTrials.gov #NCT02803086) aimed at developing predictive models of radiation-induced toxicities. Self-reported UI and personality traits, evaluated by means of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF) and Eysenck Personality Questionnaire - Revised (EPQ-R) questionnaires, were assessed at ART/SRT start. Several endpoints based on baseline ICIQ-SF were investigated: frequency and amount of urine loss (ICIQ3 and ICIQ4, respectively), "objective" UI (ICIQ3 + 4), "subjective" UI (ICIQ5), and "TOTAL" UI (ICIQ3 +4 + 5). The relationship between each endpoint and time from prostatectomy to radiotherapy (TTRT) was investigated. The association between clinical and personality variables and each endpoint was tested by uni- and multivariable logistic regression. TTRT was the strongest predictor for all endpoints ( Early UI recovery mostly depends on TTRT with no further improvement after 8 months from prostatectomy. Higher levels of neuroticism may overestimate UI.
Sections du résumé
BACKGROUND
BACKGROUND
Baseline urinary incontinence (UI) strongly modulates UI recovery after adjuvant/salvage radiotherapy (ART/SRT), inducing clinicians to postpone it "as much as possible", maximizing UI recovery but possibly reducing efficacy. This series aims to analyze the trend of UI recovery and its predictors at radiotherapy start.
METHODS
METHODS
A population of 408 patients treated with ART/SRT enrolled in a cohort study (ClinicalTrials.gov #NCT02803086) aimed at developing predictive models of radiation-induced toxicities. Self-reported UI and personality traits, evaluated by means of the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form (ICIQ-SF) and Eysenck Personality Questionnaire - Revised (EPQ-R) questionnaires, were assessed at ART/SRT start. Several endpoints based on baseline ICIQ-SF were investigated: frequency and amount of urine loss (ICIQ3 and ICIQ4, respectively), "objective" UI (ICIQ3 + 4), "subjective" UI (ICIQ5), and "TOTAL" UI (ICIQ3 +4 + 5). The relationship between each endpoint and time from prostatectomy to radiotherapy (TTRT) was investigated. The association between clinical and personality variables and each endpoint was tested by uni- and multivariable logistic regression.
RESULTS
RESULTS
TTRT was the strongest predictor for all endpoints (
CONCLUSIONS
CONCLUSIONS
Early UI recovery mostly depends on TTRT with no further improvement after 8 months from prostatectomy. Higher levels of neuroticism may overestimate UI.
Identifiants
pubmed: 34209562
pii: cancers13133243
doi: 10.3390/cancers13133243
pmc: PMC8269132
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02803086']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : IG14603
Références
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):382-388
pubmed: 31201895
J Clin Oncol. 2012 Feb 10;30(5):513-8
pubmed: 22215756
Radiother Oncol. 2017 Oct;125(1):101-106
pubmed: 28826629
J Urol. 2013 Aug;190(2):441-9
pubmed: 23707439
J Clin Oncol. 2017 Jul 10;35(20):2306-2314
pubmed: 28493812
Radiother Oncol. 2017 Aug;124(2):296-301
pubmed: 28739383
Lancet. 2020 Oct 31;396(10260):1422-1431
pubmed: 33002431
Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):690-5
pubmed: 27131081
Eur Urol Oncol. 2018 Oct;1(5):353-360
pubmed: 31158073
Lancet Oncol. 2020 Oct;21(10):1341-1352
pubmed: 33002438
Lancet. 2020 Oct 31;396(10260):1413-1421
pubmed: 33002429
Cancer Treat Rev. 2018 May;66:23-44
pubmed: 29673922
Eur Urol. 2016 Nov;70(5):751-757
pubmed: 27016464
Radiother Oncol. 2016 Jan;118(1):79-84
pubmed: 26702990
Phys Med. 2016 Mar;32(3):521-32
pubmed: 27068274
Strahlenther Onkol. 2019 Feb;195(2):131-144
pubmed: 30182246
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
J Clin Oncol. 2016 Oct 20;34(30):3648-3654
pubmed: 27528718
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2):333-340
pubmed: 27497691
Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):277-87
pubmed: 25491504
World J Urol. 2017 Dec;35(12):1841-1847
pubmed: 28861691
Can Urol Assoc J. 2014 Jul;8(7-8):253-8
pubmed: 25210549
Neurourol Urodyn. 2004;23(4):322-30
pubmed: 15227649
Eur Urol. 2014 Mar;65(3):546-51
pubmed: 23415377
Eur Urol. 2012 Jan;61(1):112-27
pubmed: 22001105
Radiother Oncol. 2008 Jul;88(1):135-9
pubmed: 18022263
Eur Urol. 2017 Mar;71(3):330-336
pubmed: 27887941
Lancet Oncol. 2020 Oct;21(10):1331-1340
pubmed: 33002437
J Urol. 2017 Mar;197(3 Pt 1):669-675
pubmed: 27670915